ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Jun 12, 2019 15:00 JST
Source:
Alset International Ltd
Global BioLife's 3F Mosquito Repellent Formula performs well in Independent Testing
SINGAPORE, Jun 12, 2019 - (ACN Newswire) - SGX-listed Singapore eDevelopment Ltd (SeD) wishes to announce that U.S. biomedical subsidiary Global BioLife Inc. has independently tested its new 3F Mosquito Formula which performs well against mosquitoes for six (6) to eight (8) hours.
In 2017, SeD announced a collaboration between Global BioLife and U.S. based Chemia Corporation to develop a suite of fragrances referred to as 3F (Functional Fragrance Formulation). Previous testing was promising for the 3F Mosquito Fragrance, which is made of specialised oils sourced from botanicals that mosquitoes avoid in varying concentrations of 0.25% to 5%.
Global BioLife contracted U.S. based Snell Scientifics, LLC in Meansville, Georgia to conduct a study on the new mosquito repellent formula and the results of the study showed that it repelled between 82% to 95% of mosquitos for six (6) hours after application.
"Utilising fragrances to repel mosquitos with this level of efficacy is a game changer for the consumer products industry," said Mr. Thomas A. Meyer, Chemia's Vice-President of Innovation and Sustainability.
Globally, an estimated 3.4 billion people in 92 countries are at risk of being infected with Zika, Dengue, West Nile Virus, Malaria and other mosquito transmitted diseases. Mosquito repellent products are key in the fight against mosquito transmitted diseases, while a product favoured by consumers is easy to apply, is considered safe, and does not have unpleasant attributes such as a strong chemical odour.
The market for safe mosquito repellents is expanding, and consumers have expressed a demand for effective mosquito repellent products with appealing scents. The most recently tested product has a fragrance that is modeled on the fresh scent of the Ghost Orchid, a rare flower known for its distinctive and pleasant aroma found in the Everglades of Florida.
"3F Mosquito works differently from traditional insect repellents. It's effective even at very low concentrations due to its multi-aspect receptor inhibition," said Mr. Daryl Thompson, Global BioLife's Director of Scientific Initiatives.
"Global BioLife is extremely proud of these test results," said SeD's Executive Chairman Mr. Chan Heng Fai. "3F is an innovative product that works in an entirely different manner from any other product on the market today. 3F is a true success for people everywhere and will help reduce the number of mosquito transmitted diseases on a global scale."
Global BioLife is currently in discussions with interested companies for potential licensing and global deployment of this new mosquito repellent formula.
About Singapore eDevelopment Limited
Incorporated on 9 September 2009 and listed on the Singapore Exchange in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg or email
contact@sed.com.sg
.
About Global BioLife Inc.
Global BioLife Inc. ("GBLI") is a 70%-held direct subsidiary of Global BioMedical Inc., which is a wholly-owned direct subsidiary of Singapore BioMedical Pte. Ltd., which in turn is a wholly-owned direct subsidiary of Singapore eDevelopment Limited, a company listed on the Singapore Exchange. The remaining shareholding of Global BioLife Inc. is held by Global Research and Discovery Group Scientific LLC ("GRDGS") at 20% and Australian Exchange-listed Holista CollTech Limited ("Holista") at 10%. For more information, please visit:
http://www.globalbiolife.com
.
About GRDG Sciences, LLC.
GRDG Sciences, LLC is an advanced research team formed in Florida by natural products discovery drug research scientist, Daryl Thompson. For more information, please visit:
http://www.globalrdg.com
.
Source: Alset International Ltd
Sectors: Healthcare & Pharm, Cosmetics, Spec.Chem
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Mitsubishi Motors Posts Record Sales in the Philippines in FY2023
Apr 24, 2024 13:56 JST
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 24, 2024 13:25 JST
Fujitsu SX Survey reveals key success factors for sustainability
Apr 23, 2024 10:25 JST
Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions
Apr 22, 2024 16:09 JST
NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II
Apr 22, 2024 15:09 JST
Soft Space Launches the First and Only JCB Payment Gateway in Malaysia
Apr 22, 2024 15:00 JST
TOYOTA GAZOO Racing takes a one-two in Croatian thriller
Apr 22, 2024 10:47 JST
First-ever Mazda CX-80 Crossover SUV Unveiled in Europe
Apr 19, 2024 13:50 JST
Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces
Apr 19, 2024 10:17 JST
Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas
Apr 18, 2024 17:01 JST
Toyota Launches All-New Land Cruiser "250" Series in Japan
Apr 18, 2024 13:39 JST
Fujitsu and Oracle collaborate to deliver sovereign cloud and AI capabilities in Japan
Apr 18, 2024 11:14 JST
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Apr 18, 2024 10:53 JST
All-New Triton Confirmed as First Double-Cab Pickup Truck to Achieve 2024 Five-Star ANCAP Safety Rating
Apr 18, 2024 09:22 JST
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
Apr 17, 2024 16:17 JST
Honda Unveils Next-generation EV Series for China
Apr 17, 2024 12:15 JST
Lexus presents Time at the 2024 Milan Design Week
Apr 16, 2024 18:49 JST
Mitsubishi Corporation Announces Participation in a DAC Project in Louisiana, USA
Apr 16, 2024 14:36 JST
New circuit challenge for TOYOTA GAZOO Racing
Apr 15, 2024 17:21 JST
TOYOTA GAZOO Racing back on asphalt for Croatian challenge
Apr 12, 2024 19:36 JST
More Latest Release >>
Related Release
Alset International Ltd establishes Alset Mining Pte Ltd to embark on cryptocurrency mining activities
March 23 2022 09:00 JST
Alset Capital Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option
February 21 2022 12:00 JST
Impact BioMedical to Begin Efficacy Testing Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc.
October 05 2020 15:25 JST
Impact BioMedical Demonstrates 10-Fold Reduction in Viral Population of COVID-19 in Surface Disinfectant Efficacy Testing of its 3F Antiviral Biofragrance
September 18 2020 17:00 JST
Impact Biomedical initiates Quantum, a new frontier in Pharmaceutical Development
July 31 2020 15:00 JST
Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance
June 24 2020 14:00 JST
Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal
June 17 2020 18:00 JST
Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts
June 01 2020 13:00 JST
Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts
April 24 2020 10:00 JST
Impact BioMedical's Linebacker and Equivir inhibit SARS-CoV-2, virus responsible for the COVID-19 outbreak
March 18 2020 11:00 JST
More Press release >>